Literature DB >> 27446408

PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway.

Jianyi Yang1, Xuejun Gong1, Lu Ouyang1, Wen He1, Rou Xiao1, Li Tan1.   

Abstract

Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchanger factor 2 (PREX2) is a novel regulator of the small guanosine triphosphatase Rac, and has been observed to be implicated in human cancer by inhibiting the activity of phosphatase and tensin homolog (PTEN), thus upregulating the activity of the phosphoinositide 3-kinase (PI3K) signaling pathway. However, the exact role of PREX2 in pancreatic cancer has not been reported to date. In the present study, the expression levels of PREX2 were observed to be frequently increased in pancreatic cancer specimens compared with those in their matched adjacent normal tissues. In addition, PREX2 expression was also frequently upregulated in several pancreatic cancer cell lines, including AsPC-1, BxPC-3, PANC-1 and CFAPC-1, compared with that in the normal pancreatic epithelial cell line HPC-Y5. Overexpression of PREX2 significantly promoted the proliferation, invasion and migration of pancreatic cancer PANC-1 cells, while small interfering RNA-induced knockdown of PREX2 expression significantly inhibited the proliferation, invasion and migration of these cells. Investigation of the molecular mechanism revealed that the overexpression of PREX2 upregulated the phosphorylation levels of PTEN, indicating that the activity of PTEN was reduced, which further increased the phosphorylation levels of AKT, which indicated that the activity of the PI3K signaling pathway was upregulated. By contrast, knockdown of PREX2 upregulated the activity of PTEN and inhibited the activity of the PI3K signaling pathway. In conclusion, the present study demonstrated that PREX2 regulates the proliferation, invasion and migration of pancreatic cancer cells, probably at least via modulation of the activity of PTEN and the PI3K signaling pathway.

Entities:  

Keywords:  invasion; migration; pancreatic cancer; phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchanger factor 2

Year:  2016        PMID: 27446408      PMCID: PMC4950779          DOI: 10.3892/ol.2016.4688

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

Review 1.  Pancreatic cancer: medical management (novel chemotherapeutics).

Authors:  David Páez; Melissa J Labonte; Heinz-Josef Lenz
Journal:  Gastroenterol Clin North Am       Date:  2012-01-15       Impact factor: 3.806

Review 2.  Addressing the challenges of pancreatic cancer: future directions for improving outcomes.

Authors:  Manuel Hidalgo; Stefano Cascinu; Jörg Kleeff; Roberto Labianca; J-Matthias Löhr; John Neoptolemos; Francisco X Real; Jean-Luc Van Laethem; Volker Heinemann
Journal:  Pancreatology       Date:  2014-10-17       Impact factor: 3.996

3.  miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a.

Authors:  Xin Chen; Min Pan; Lulu Han; Hongting Lu; Xiwei Hao; Qian Dong
Journal:  FEBS Lett       Date:  2013-10-15       Impact factor: 4.124

4.  Molecular pathways: P-Rex in cancer.

Authors:  Atanasio Pandiella; Juan Carlos Montero
Journal:  Clin Cancer Res       Date:  2013-06-10       Impact factor: 12.531

5.  Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.

Authors:  Edoardo Missiaglia; Irene Dalai; Stefano Barbi; Stefania Beghelli; Massimo Falconi; Marco della Peruta; Lorenzo Piemonti; Gabriele Capurso; Alessia Di Florio; Gianfranco delle Fave; Paolo Pederzoli; Carlo M Croce; Aldo Scarpa
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

6.  miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a.

Authors:  Bo Guo; Liying Liu; Jiayi Yao; Ruili Ma; Dongmin Chang; Zongfang Li; Tusheng Song; Chen Huang
Journal:  Mol Cancer Res       Date:  2013-12-27       Impact factor: 5.852

7.  Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.

Authors:  Barry Fine; Cindy Hodakoski; Susan Koujak; Tao Su; Lao H Saal; Matthew Maurer; Benjamin Hopkins; Megan Keniry; Maria Luisa Sulis; Sarah Mense; Hanina Hibshoosh; Ramon Parsons
Journal:  Science       Date:  2009-09-04       Impact factor: 47.728

8.  Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.

Authors:  H Zhao; L Wang; R Wei; D Xiu; M Tao; J Ke; Y Liu; J Yang; T Hong
Journal:  Diabetes Obes Metab       Date:  2014-04-15       Impact factor: 6.577

9.  Melanoma genome sequencing reveals frequent PREX2 mutations.

Authors:  Michael F Berger; Eran Hodis; Timothy P Heffernan; Yonathan Lissanu Deribe; Michael S Lawrence; Alexei Protopopov; Elena Ivanova; Ian R Watson; Elizabeth Nickerson; Papia Ghosh; Hailei Zhang; Rhamy Zeid; Xiaojia Ren; Kristian Cibulskis; Andrey Y Sivachenko; Nikhil Wagle; Antje Sucker; Carrie Sougnez; Robert Onofrio; Lauren Ambrogio; Daniel Auclair; Timothy Fennell; Scott L Carter; Yotam Drier; Petar Stojanov; Meredith A Singer; Douglas Voet; Rui Jing; Gordon Saksena; Jordi Barretina; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Melissa Parkin; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jennifer Wargo; Dirk Schadendorf; Matthew Meyerson; Stacey B Gabriel; Todd R Golub; Stephan N Wagner; Eric S Lander; Gad Getz; Lynda Chin; Levi A Garraway
Journal:  Nature       Date:  2012-05-09       Impact factor: 49.962

10.  Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients.

Authors:  Jie Xu; Zhaoli Li; Jilin Wang; Haoyan Chen; Jing-Yuan Fang
Journal:  Transl Oncol       Date:  2014-03-04       Impact factor: 4.243

View more
  4 in total

1.  Comprehensive characterization of posttranscriptional impairment-related 3'-UTR mutations in 2413 whole genomes of cancer patients.

Authors:  Wenqing Wei; Wenyan Gao; Qinglan Li; Yuhao Liu; Hongyan Chen; Yongping Cui; Zhongsheng Sun; Zhihua Liu
Journal:  NPJ Genom Med       Date:  2022-06-02       Impact factor: 6.083

2.  Nomogram model characterized by mutant genes and clinical indexes to identify high-risk patients with stage III/IV colorectal cancer.

Authors:  Kai Liu; Cui Wang; Jiefu Wang; Yang Zhan; Xin Yue; Dalu Kong
Journal:  J Gastrointest Oncol       Date:  2020-12

3.  Haplotype-resolved and integrated genome analysis of the cancer cell line HepG2.

Authors:  Bo Zhou; Steve S Ho; Stephanie U Greer; Noah Spies; John M Bell; Xianglong Zhang; Xiaowei Zhu; Joseph G Arthur; Seunggyu Byeon; Reenal Pattni; Ishan Saha; Yiling Huang; Giltae Song; Dimitri Perrin; Wing H Wong; Hanlee P Ji; Alexej Abyzov; Alexander E Urban
Journal:  Nucleic Acids Res       Date:  2019-05-07       Impact factor: 16.971

4.  Detecting Blood Methylation Signatures in Response to Childhood Cancer Radiotherapy via Machine Learning Methods.

Authors:  Zhandong Li; Wei Guo; Shijian Ding; Kaiyan Feng; Lin Lu; Tao Huang; Yudong Cai
Journal:  Biology (Basel)       Date:  2022-04-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.